scholarly journals Prediction of Cost-effectiveness for Human Immunodeficiency Virus (HIV) Screening Program in Japan

1995 ◽  
Vol 5 (1) ◽  
pp. 35-41
Author(s):  
Mahbubur Rahman ◽  
Takashi Tsutsui ◽  
Isao Kamae ◽  
Takashi Takahashi
Keyword(s):  
Human Immunodeficiency Virus ◽  
Cost Effectiveness ◽  
Screening Program ◽  
Hiv Screening ◽  
Immunodeficiency Virus

scholarly journals Economic evaluation, human immunodeficiency virus infection and screening: A review and critical appraisal of economic studies

2010 ◽  
Vol 26 (3) ◽  
pp. 301-308 ◽  
Author(s):  
Onome Dibosa-Osadolor ◽  
Tracy Roberts
Keyword(s):  
Human Immunodeficiency Virus ◽  
Economic Evaluation ◽  
Cost Effectiveness ◽  
Hiv Infection ◽  
Economic Evaluations ◽  
Hiv Screening ◽  
Cost Study ◽  
Life Years ◽  
Immunodeficiency Virus ◽  
Static Models

Objectives: The aim of this study was to review, systematically and critically, evidence used to derive estimates of cost-effectiveness of human immunodeficiency virus (HIV) screening.Methods: A systematic review was conducted. Searched were three main electronic bibliographic databases from 1993 to 2008 using key words including HIV, mass screening, HAART, economic evaluation, cost-effectiveness analysis, modeling. We included studies of sexually transmitted HIV infection in both sexes, including studies comparing diagnostic testing protocols and partner notification. Outcomes included were cases of HIV infection detected, deterioration to the AIDS state, secondary transmission of HIV, the quality-adjusted life-years/survival, costs, and cost-effectiveness of HIV screening.Results: Eighty-four papers were identified; ten of which were formal economic evaluations, one cost study, three effectiveness studies, and three systematic reviews of HIV prevention programs. The predominant assertion was that HIV screening is cost-effective; methodological problems, such as the preponderance of static models which are inappropriate for infectious diseases, varying perspectives from which the studies were analyzed, and arbitrary threshold incremental cost-effectiveness ratio levels, limited the validity of these findings, and their usefulness in informing health policy decisions.Conclusions: The majority of published economic evaluations are based on inappropriate static models. This flaw renders the results of these studies as inconclusive and the purported cost-effectiveness of HIV screening debatable. The results of this review could form a basis for consideration of further research and analysis by health economists into the cost-effectiveness of HIV screening.

scholarly journals 1061. False Positive Human Immunodeficiency Virus Testing Due to Acute Hepatitis A Infection: A Case Series

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S559-S559
Author(s):  
Maria V Bandres ◽  
Daniel Mueller
Keyword(s):  
Human Immunodeficiency Virus ◽  
Acute Hepatitis ◽  
Hiv Testing ◽  
False Positive ◽  
Hepatitis A ◽  
Screening Tests ◽  
Hiv Screening ◽  
Immunodeficiency Virus ◽  
Acute Hepatitis A ◽  
Hiv 1

Abstract Background In our urban, underserved patient population, Human Immunodeficiency Virus (HIV) is hyper-endemic, and HIV screening is frequently performed. Although HIV screening tests have high specificity, false positives can occur. Numerous reasons for false positive testing have been cited, including vaccinations, autoimmune diseases, and viral infections. In 2019, Philadelphia experienced a large Hepatitis A outbreak, during which time false positive HIV screening tests were discovered. Our aim was to further describe these patients who had been diagnosed with acute Hepatitis A infection and in whom false positive HIV testing had occurred. Methods We conducted a retrospective chart review of adult patients admitted to our hospital between January 2017 and December 2019 who had a positive Hepatitis A Virus (HAV) IgM. Demographics, HIV tests, viral hepatitis tests, and liver tests were recorded. False positive HIV was defined as a positive HIV screen (p24 antigen and HIV-1 and 2 antibody combo), followed by a negative differentiation assay for HIV-1 and 2 antibodies, combined with a negative HIV PCR. Results A total of 156 unique patients were found to have acute HAV, with 138 cases identified in 2019. Of these, 3 patients had confirmed false positive HIV testing, and 1 patient had suspected false positive HIV testing (HIV-2 differentiation assay indeterminate, with very low local prevalence of HIV-2), for a false positive test rate of 2.6% (4/156). Ages ranged from 36-47 years, 3 were male, and 2 were persons who injected drugs (PWID). Three patients had prior negative HIV testing. Two patients had fevers during admission, but none of the four were febrile at the time of HIV test collection. Three patients had elevated transaminases, and two had abnormal coagulation testing. Coinfection with Hepatitis C was found in three patients. One patient had follow-up HIV testing performed, which was negative. Conclusion To our knowledge, this is the first report of false positive HIV testing related to acute HAV. Prevalence of false positives was low, but awareness can facilitate patient counseling. With low sample size, conclusions cannot be drawn about risk factors related to false positive testing. Disclosures All Authors: No reported disclosures

Sign in / Sign up

Export Citation Format

Share Document